Precision Medicine & Diagnostics
Foundation Medicine
by Foundation Medicine, Inc.
Comprehensive genomic profiling that matches cancer patients to targeted therapies and clinical trials
Category
Precision Medicine & Diagnostics
Founded
2010
Headquarters
Cambridge, MA, USA
Overview
Foundation Medicine is the global leader in comprehensive genomic profiling (CGP) for cancer, offering tissue-based and liquid biopsy tests that analyze hundreds of cancer-related genes to identify clinically relevant genomic alterations. Its flagship tests — FoundationOne CDx and FoundationOne Liquid CDx — are FDA-approved companion diagnostics that detect substitutions, insertions/deletions, copy number alterations, rearrangements, and genomic signatures such as tumor mutational burden (TMB) and microsatellite instability (MSI) from a single sample. Oncologists, pathologists, and pharmaceutical companies rely on Foundation Medicine to guide treatment decisions and match patients with targeted therapies, immunotherapies, and clinical trials. The FoundationOne CDx is the FDA-approved companion diagnostic for over 20 targeted therapies across multiple tumor types. Pharma companies use Foundation Medicine's real-world genomic database and companion diagnostic development services to support drug approvals and enrich clinical trials. A wholly-owned subsidiary of Roche since 2018, Foundation Medicine benefits from Roche's global oncology commercial infrastructure and diagnostic capabilities. The company has profiled over one million cancer patients and maintains one of the world's largest pan-cancer genomic databases, which drives continuous biomarker discovery and expands the clinical utility of CGP beyond initial treatment selection to disease monitoring and resistance analysis.
Key Features
Clinical Trial Matching
Automated matching of patients to clinical trials based on genomic profiles and eligibility criteria.
Multi-Modal Patient Profiling
Integration of genomic, clinical, imaging, and real-world data for comprehensive patient profiles.
Genomic Biomarker Discovery
AI-powered analysis of clinical sequencing data identifies actionable biomarkers in hours.
Regulatory Submission Support
Automated documentation and evidence packages for FDA submission of diagnostic tests.
Population Health Analytics
Large-scale population genomic analysis to identify disease risk factors and health disparities.
Pros & Cons
Pros
- +AI-powered genomic analysis identifies actionable biomarkers from clinical sequencing data in hours
- +Longitudinal patient tracking enables outcomes-based analysis of treatment effectiveness
- +Partnerships with 50%+ of US academic medical centers provide diverse patient population coverage
- +FDA-cleared diagnostic tests validate AI-driven biomarker discoveries for clinical use
- +Companion diagnostic development accelerates clinical trial matching and treatment selection
- +Real-world evidence platform aggregates de-identified patient data from major healthcare systems
Cons
- −Reimbursement pathways for AI-driven diagnostics remain uncertain in many healthcare markets
- −Requires high-quality, diverse patient datasets that may not be available for rare diseases
- −Clinical validation and regulatory approval processes are lengthy and resource-intensive
- −Clinical adoption depends on physician trust in AI-generated recommendations
- −Privacy and consent requirements for patient data use add complexity and cost
Use Cases
Genomic-Guided Treatment Selection
AI-powered analysis of patient genomic data to identify actionable biomarkers and match patients to optimal therapies.
Clinical Trial Matching
Automated matching of patients to clinical trials based on genomic profile, medical history, and trial eligibility criteria.
Real-World Evidence Generation
Aggregation and analysis of de-identified patient data from healthcare systems to generate real-world evidence.